GenVec, Inc., is a biopharmaceutical company developing therapeutic drugs for cancer and vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), HSV-2, and influenza. GenVec was acquired by Intrexon on June 16, 2017.
